Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2331 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis
J. R. Curtis¹, H. Schulze-Koops², L Takiya³, C. A. Mebus⁴, K. Terry⁴, R. Chew⁴ and T. V. Jones³, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Munich, Munich, Germany, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The clinical development program for tofacitinib in RA enrolled ˃500…
Abstract Number: 1726 • 2013 ACR/ARHP Annual Meeting
Survivin Inhibition Disturbs Bcl-6 and Blimp-1 Control Of Lymphocyte Maturation and Alleviates Antigen-Induced Arthritis
Mattias Svensson¹, Karin Andersson¹, Malin Erlandsson¹, Ing-Marie Jonsson² and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden
Background/Purpose: Survivin is a proto-oncogene known to regulate cell division and apoptosis. In patients with rheumatoid arthritis, survivin has emerged as an independent predictor of…
Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
X. Mariette¹, J. R. Curtis², E. B. Lee³, B. Benda⁴, I. Kaplan⁵, K. Soma⁵, R. Chew⁵, J. Geier⁶, L. Wang⁷ and R. Riese⁵, ¹Paris-Sud University, Paris, France, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Worldwide R&D, Cambridge, MA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…
Abstract Number: L12 • 2013 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Demonstrates Efficacy and Significantly Reduces Proinflammatory Cytokines in Patients with Active Longstanding Rheumatoid Arthritis with High Gonadotropin Levels: A Proof-of-Concept, Double-Blind, Randomized Trial
Anita Kåss^1,2, Ivana Hollan³, Peter Torjesen⁴, Hans Christian Gulseth⁵ and Øystein T. Førre⁶, ¹Faculty of Medicine, University of Oslo, Oslo, Norway, ²Dept. of Rheumatology, Betanien Hospital, Skien, Norway, ³Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Department of Endocrinology, Oslo University Hospital, Oslo, Norway, ⁵Rheumatology, Betanien Hospital, Skien, Norway, ⁶Oslo University Hospital, Oslo, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1). Inhibiting GnRH, by…
Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
W. F. C. Rigby¹, L. Takiya², S. P. Wood³, H. Fan² and T. V. Jones², ¹Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
Abstract Number: 1441 • 2013 ACR/ARHP Annual Meeting
Predictive Factors Of Response To Tocilizumab In Patients With Active Rheumatoid Arthritis
Maria Victoria Hernández¹, Javier Narvaez², Raimon Sanmarti³, Delia Reina⁴, Cesar Diaz-Torne⁵, Berta Magallares⁵, Arturo Rodriguez de la Serna⁵, José María Llobet⁵, Hector Corominas⁴ and Joan Miquel Nolla², ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁵Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: To analyze the efficacy and identify predictors of response to tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). Methods: A multicenter ambispective observational study…
Abstract Number: 460 • 2013 ACR/ARHP Annual Meeting
Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W.J. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: To compare ACR responses of novel DMARDs as monotherapy or in combination with methotrexate (MTX), including subcutaneous (SC) abatacept and SC tocilizumab (TCZ), in…
Abstract Number: 2321 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study
Josef S. Smolen¹, Ronald van Vollenhoven², Arthur Kavanaugh³, Vibeke Strand⁴, Jiri Vencovsky⁵, Michael H. Schiff⁶, Robert Landewé⁷, Boulos Haraoui⁸, Susan Walker⁹ and Désirée van der Heijde¹⁰, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁵Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹UCB Pharma, Raleigh, NC, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…
Abstract Number: 1418 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
J. M. Kremer¹, J. D. Greenberg², C. Turesson³, D. Gruben⁴, C. A. Mebus⁴, E. Bananis⁵ and T. Robinson⁶, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ³Lund University, Malmö, Sweden, ⁴Pfizer Inc, Groton, CT, ⁵Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Cigarette smoking is a known risk factor for developing rheumatoid arthritis (RA).1 Several recent observational studies suggest that cigarette smoking may be associated with…
Abstract Number: 472 • 2013 ACR/ARHP Annual Meeting
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Julie Azaïs¹, Thomas Barnetche², Pascale Vergne-Salle³, Christine Bonnet⁴, Carine Dufauret-Lombard⁵, Richard Treves⁶ and Philippe Bertin⁷, ¹Rheumatology department, CHU Dupuytren Limoges, Limoges, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, CHU Dupuytren Limoges, limoges, France, ⁴department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁵Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁶Department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁷Service De Rhumatologie, CHU Dupuytren Limoges, Limoges, France
Background/Purpose: Therapeutics generate non-specific effects (the placebo effect), and specific ones, like the 5 tumor necrosis factor (TNF) inhibitors used in the treatment of Rheumatoid…
Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Ketti K. Terry⁴, Hiroyuki Nakamura⁵, Yukako Ohno⁵, David Gruben⁴, Birgitta Benda⁶, Lisy Wang⁴ and Richard Riese⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 1426 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Spermidine/Spermine N1-Acetyltransferase Activity – a New Therapeutical Concept In Rheumatoid Arthritis
Emmanuel Karouzakis¹, Astrid Jungel¹, Beat A. Michel², Renate E. Gay³, Steffen Gay¹ and Michel Neidhart⁴, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Spermine/spermidine N1-acetyltransferase (SSAT1) and polyamine modulating factor 1 (PMF1) are increased in rheumatoid arthritis synovial fibroblasts (RASF). Since PMF1 regulates the expression of SSAT1,…
Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
C. Charles-Schoeman¹, P Wicker², M. A. Gonzalez-Gay³, S. P. Wood⁴, M.G. Boy⁴, J. Geier⁵, D. Gruben⁴, K. Soma⁴ and R. Riese⁴, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²PW Consulting LLC, Mystic, CT, ³Reumatologia, Hospital Marques De Valdecilla, Santander, Spain, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…
Abstract Number: 2075 • 2012 ACR/ARHP Annual Meeting
CCR6⁺Foxp3⁺ Regulatory T Cells Regulate the Development of Collagen Induced Arthritis in T Cell Specific RORγt Transgenic Mice
Yuya Kondo¹, Masahiro Tahara¹, Mana Iizuka¹, Hiroto Tsuboi¹, Satoru Takahashi², Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Anatomy and Embryology, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Recent studies reported that IL-17 producing Th-17 cells appear to play an important role in the generation of several autoimmune arthritis models. We previously…
Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
D. van der Heijde¹, Y. Tanaka², Roy Fleischmann³, Edward Keystone⁴, Joel M. Kremer⁵, C. Zerbini⁶, M. H. Cardiel⁷, S. B. Cohen⁸, P. T. Nash⁹, Y. Song¹⁰, D. Tegzova¹¹, B. Wyman¹², D. Gruben¹², B. Benda¹³, G. Wallenstein¹⁴, S. Krishnaswami¹², S. H. Zwillich¹², J. Bradley¹⁵, C. A. Connell¹⁶ and ORAL Scan Investigators¹⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁵The Center for Rheumatology, Albany Medical College, Albany, NY, ⁶CEPIC – Centro Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, Brazil, ⁷Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁸Metroplex Clinical Research Centre, Dallas, TX, ⁹Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, ¹⁰Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Pfizer Inc., Groton, CT, ¹³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ¹⁴Pfizer Inc, New York, NY, ¹⁵Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ¹⁶Pfizer Inc, Groton, CT, ¹⁷Groton
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].